Joyson Poulose, MD
Hematology & Oncology · Sayre, PANPI 1134561632
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,775 of the $2,908 with a category attached, or 95.4%. AstraZeneca accounts for 72.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $2,867 and has fallen 99.4% since, to $17 in 2025.
Across 12 payments — averaging $242.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Beigene USA, Inc.$675
- Merck$35
- E.r. Squibb & Sons, L.L.C.$25
- Puma Biotechnology, Inc.$24
- AbbVie$17
- plus $32 from 2 others
Across 45 payments — averaging $9300.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$175K
- Amgen$113K
- AbbVie$86K
- Biontech SE$17K
- Sumitomo Pharma America, Inc.$14K
- E.r. Squibb & Sons, L.L.C.$13K
What the payments were for
- Consulting fees$2,77595%
- Food & beverage$903%
- Education$431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $2,100 |
| Beigene USA, Inc. | 1 | $675 |
| Merck | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Puma Biotechnology, Inc. | 1 | $24 |
| AbbVie | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,908 in reported general payments places this provider in the 55th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 16 | $57,650 |
| OrgovyxRelugolix | 11 | $30,374 |
| EliquisApixaban | 14 | $10,292 |
| Anastrozole | 28 | $923 |
| Dexamethasone | 30 | $578 |
| Prochlorperazine Maleate | 31 | $565 |
| Oxycodone Hcl | 17 | $232 |
| Prednisone | 18 | $96 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Sayre
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.